Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This is a phase II study of the combination of the GITR agonist monoclonal antibody
INCAGN01876, the anti-PD1 monoclonal antibody INCMGA00012, and stereotactic radiosurgery
(SRS) for recurrent Glioblastoma (GBM). The investigators hypothesize that the proposed
regimen will be safe and stimulate a robust anti-tumor immune response and result in improved
tumor responses.